Silo Pharma Finalizes Sublicense Deal for its Targeted Psilocybin Cancer Therapeutic Technology
April 07, 2021 08:01 ET
|
Silo Pharma, Inc.
Agreement to explore the use of Silo Pharma’s Novel Peptide Englewood Cliffs, NJ, April 07, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company...
Silo Pharma, Inc. Enters into an Exclusive Option Agreement with the University of Maryland, Baltimore for patented Homing Peptides Targeting Rheumatoid Arthritis
March 04, 2021 08:44 ET
|
Silo Pharma, Inc.
Englewood Cliffs NJ, March 04, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTC QB: SILO), a developmental stage biopharmaceutical company, today announced that it has executed an exclusive option...
Silo Pharma to Present at Proactive's One2One Virtual Investor Forum
February 23, 2021 08:15 ET
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic...
Silo Pharma Licenses Novel Peptide-Guided Drug Delivery Approach for the Treatment of MS
February 18, 2021 08:15 ET
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic...
Silo Pharma Announces Private Placement of Equity Definitive Agreement for $4.275 Million in Gross Proceeds
February 10, 2021 08:45 ET
|
Silo Pharma, Inc.
Silo Pharma to pursue additional strategic partnerships and intellectual property acquisitions in the psychedelic medicine space Englewood Cliffs, NJ, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Silo...
Silo Pharma Reaches Terms with University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease
January 26, 2021 08:18 ET
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic...
Silo Pharma to Participate in Virtual Conference on Investing in Psychedelics
January 19, 2021 08:13 ET
|
Silo Pharma, Inc.
NEW JERSEY , Jan. 19, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research...
Silo Pharma Enters into Sponsored Research Agreement for Potential Multiple Sclerosis Treatment Approach with University of Maryland, Baltimore
January 13, 2021 08:45 ET
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic...
Silo Pharma Provides Details of Patent License Agreement for Psilocybin and Cancer Applications
January 11, 2021 08:30 ET
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, last week...
Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities
January 06, 2021 08:15 ET
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today...